Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lowered by Oppenheimer from $53.00 to $52.00 in a research report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. increased their price […]
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target […]
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 EPS estimates for Kymera Therapeutics in a research note issued to investors on Friday, February 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.79) for the quarter. The consensus […]